Qube Research & Technologies LTD Oramed Pharmaceuticals Inc. Transaction History

Qube Research & Technologies LTD

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.07 - $2.83 $182,344 - $249,291	-88,089 Reduced 99.88%	107 $0
Q1 2024 May 14, 2024	BUY	$2.18 - $3.58 $3,653 - $6,000	1,676 Added 1.94%	88,196 $257,000
Q4 2023 Feb 13, 2024	BUY	$1.71 - $2.57 $131,037 - $196,939	76,630 Added 774.82%	86,520 $199,000
Q3 2023 Nov 13, 2023	BUY	$2.51 - $3.55 $24,823 - $35,109	9,890 New	9,890 $25,000
Q1 2023 May 15, 2023	SELL	$1.93 - $13.1 $22,237 - $150,938	-11,522 Reduced 26.9%	31,309 $68,000
Q4 2022 Feb 14, 2023	BUY	$5.88 - $12.03 $82,531 - $168,853	14,036 Added 48.74%	42,831 $515,000
Q3 2022 Nov 14, 2022	SELL	$4.6 - $9.91 $111,931 - $241,140	-24,333 Reduced 45.8%	28,795 $187,000
Q2 2022 Aug 15, 2022	SELL	$3.72 - $9.0 $11,978 - $28,980	-3,220 Reduced 5.71%	53,128 $243,000
Q1 2022 May 09, 2022	SELL	$8.19 - $13.89 $69,213 - $117,384	-8,451 Reduced 13.04%	56,348 $487,000
Q4 2021 Feb 01, 2022	BUY	$12.98 - $29.75 $841,091 - $1.93 Million	64,799 New	64,799 $925,000
Q3 2021 Nov 12, 2021	SELL	$12.13 - $23.82 $199,016 - $390,814	-16,407 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$8.34 - $14.59 $136,834 - $239,378	16,407 New	16,407 $220,000
Q1 2021 May 14, 2021	SELL	$4.22 - $11.33 $229,108 - $615,117	-54,291 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$2.48 - $4.64 $52,337 - $97,922	-21,104 Reduced 27.99%	54,291 $230,000
Q3 2020 Nov 12, 2020	BUY	$2.58 - $4.16 $152,746 - $246,288	59,204 Added 365.66%	75,395 $197,000
Q2 2020 Aug 14, 2020	BUY	$2.87 - $4.12 $46,468 - $66,706	16,191 New	16,191 $57,000

7.4M

2.1K

Ticker ORMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,100
Market Cap $92M
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.